Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Olaf Burkhardt & Tobias Welte. (2009) 10 years’ experience with the pneumococcal quinolone moxifloxacin. Expert Review of Anti-infective Therapy 7:6, pages 645-668.
Read now
Read now
Ilias I Siempos, Argyris Michalopoulos & Matthew E Falagas. (2009) Treatment of acute bacterial exacerbations of chronic bronchitis. Expert Opinion on Pharmacotherapy 10:7, pages 1173-1182.
Read now
Read now
Articles from other publishers (20)
Radha Gopalaswamy, Nandhini Palani, Dinesh Viswanathan, Bershila Preysingh, Suchithra Rajendran, Vaishnavee Vijayaraghavan, Kannadasan Thangavel, Senthil Devi Vadivel, Hannah Stanley, Kannan Thiruvengadam, Lavanya Jayabal, Kaleeswari Murugesan, Sridhar Rathinam, Asha Frederick, Gomathi Sivaramakrishnan, Chandrasekaran Padmapriyadarsini & Sivakumar Shanmugam. (2023) Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India. Medicina 59:6, pages 1005.
Crossref
Crossref
Banafshe Abadi, Mehran Ilaghi, Yasamin Shahsavani, Mahsa Faramarzpour, Mohammad Bagher Oghazian & Hamid-Reza Rahimi. (2023) Antibiotics with Antiviral and Anti-Inflammatory Potential Against
Covid-19: A Review. Current Reviews in Clinical and Experimental Pharmacology 18:1, pages 51-63.
Crossref
Crossref
Atiqah Amran, Ching Yee Tan, Ka‐Liong Tan, Ranald Malcom Ho, Anil Kumar Anand & Chuei Wuei Leong. (2021) Pharmacokinetics and Bioequivalence Study of a New Branded Generic Moxifloxacin Tablet Among Healthy Volunteers. Clinical Pharmacology in Drug Development 10:12, pages 1514-1518.
Crossref
Crossref
Mohammad Darvishi, Shahrzad Farahani & Azadeh Haeri. (2021) Moxifloxacin-Loaded Lipidic Nanoparticles for Antimicrobial Efficacy. Current Pharmaceutical Design 27:1, pages 135-140.
Crossref
Crossref
Du, Zhang, Hou, Zhao & Li. (2019) Combined 2D-QSAR, Principal Component Analysis and Sensitivity Analysis Studies on Fluoroquinolones’ Genotoxicity. International Journal of Environmental Research and Public Health 16:21, pages 4156.
Crossref
Crossref
Zhenyu Qiu, Hongxia Yuan, Na Li, Xinjuan Yang, Xuemei Hu, Fengtai Su & Baiyi Chen. (2018) Bidirectional effects of moxifloxacin on the pro‑inflammatory response in lipopolysaccharide‑stimulated mouse peritoneal macrophages. Molecular Medicine Reports.
Crossref
Crossref
Polina German, Anita Mathias, Diana M. Brainard, Qinghua Song, John Ling & Brian P. Kearney. (2018) A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects. Clinical Pharmacology in Drug Development 7:6, pages 641-651.
Crossref
Crossref
Omid Moradi Moghadam, Reza Ghanbarpour, Mohammad Niakan, Mahshid Talebi Taher, Valiollah Hassani, Alireza Dadashi & Ebad Shiri. (2018) Assessment of Renal Damage in Patients with Multi-Drug Resistant Strains of Pneumonia Treated with Colistin. Trauma Monthly 23:1.
Crossref
Crossref
Tim Rahmel, Sven Asmussen, Jan Karlik, Jörg Steinmann, Michael Adamzik & Jürgen Peters. (2017) Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS. BMC Anesthesiology 17:1.
Crossref
Crossref
Xinnuo Xiong, Jiawei He, Hongqin Yang, Peixiao Tang, Bin Tang, Qiaomei Sun & Hui Li. (2017) Investigation on the interaction of antibacterial drug moxifloxacin hydrochloride with human serum albumin using multi-spectroscopic approaches, molecular docking and dynamical simulation. RSC Adv. 7:77, pages 48942-48951.
Crossref
Crossref
Terry King-Wing Ma, Chi Bon Leung, Kai Ming Chow, Bonnie Ching-Ha Kwan, Philip Kam-Tao Li & Cheuk Chun Szeto. (2016) Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. Clinical Kidney Journal 9:4, pages 616-623.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
645
667
.
Young R. Lee, Danni McMahan, Catherine McCall & Gregory K. Perry. (2015) Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players. Drugs 75:18, pages 2097-2117.
Crossref
Crossref
Ilija Kuzman, Alexandr Bezlepko, Irena Kondova Topuzovska, László Rókusz, Liudmyla Iudina, Hans-Peter Marschall & Thomas Petri. (2014) Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulmonary Medicine 14:1.
Crossref
Crossref
Shivam Om Mittal, Duarte Goncalves Machado & Bahman Jabbari. (2012) Orofacial Dyskinesia After Moxifloxacin Treatment—A Case With Normal Hepatorenal Function and Review of Literature. Clinical Neuropharmacology 35:6, pages 292-294.
Crossref
Crossref
Paul M. Tulkens, Pierre Arvis & Frank Kruesmann. (2012) Moxifloxacin Safety. Drugs in R&D 12:2, pages 71-100.
Crossref
Crossref
Paul M. Tulkens, Pierre Arvis & Frank Kruesmann. (2012) Moxifloxacin Safety. Drugs in R&D 12:2, pages 71-100.
Crossref
Crossref
Antonio Anzueto & Marc Miravitlles. (2010) Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respiratory Medicine 104:10, pages 1396-1403.
Crossref
Crossref
Dong Wang, Ying Wang & You-ning Liu. (2010) Experimental pulmonary infection and colonization of Haemophilus influenzae in emphysematous hamsters. Pulmonary Pharmacology & Therapeutics 23:4, pages 292-299.
Crossref
Crossref
Julien Brillault, Whocely Victor De Castro, Thomas Harnois, Alain Kitzis, Jean-Christophe Olivier & William Couet. (2009) P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model. Antimicrobial Agents and Chemotherapy 53:4, pages 1457-1462.
Crossref
Crossref